semaglutide cv benefit Cardiovascular risk reduction with once-weekly in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline risk profile in the SUSTAIN 6 trial Evaluating the Cardiovascular Benefits of
Description
El estudio publicado por Jama Internal Medicine recuerda que, para mantener el balance energtico y dado que estos frmacos reducen el apetito, hay que mantener la energa con comidas ms pequeas y refrigerios saludables, como fruta, frutos secos o yogur sin azcar

Clinical trials show that patients taking semaglutide lose 1522% of their body weight, and many experience modest blood pressure reductions as a direct result of weight loss itself
The Phase 2 trial (Jastreboff et al., NEJM 2023) tested doses from 0.5mg to 12mg

Lancet 2021;398:262-76

According to research studies, semaglutide (Wegovy) reduces 10-15% of body weight when used for long periods

As body mass declines, fewer calories are required to maintain basic physiological functions and support daily activities
